Matinas biopharma announces dsmb approval to commence part 2 of enact study of mat2203 for treatment of cryptococcal meningitis

Matinas biopharma announces dsmb approval to commence part 2 of enact study of mat2203 (oral amphotericin b) for treatment of cryptococcal meningitis.matinas biopharma - part 2 efficacy portion of enact expected to commence q1 2020.
MTNB Ratings Summary
MTNB Quant Ranking